CO6531489A2 - Anticuerpo anti -tslp modificado por técnicas de ingenieria genética - Google Patents
Anticuerpo anti -tslp modificado por técnicas de ingenieria genéticaInfo
- Publication number
- CO6531489A2 CO6531489A2 CO12068980A CO12068980A CO6531489A2 CO 6531489 A2 CO6531489 A2 CO 6531489A2 CO 12068980 A CO12068980 A CO 12068980A CO 12068980 A CO12068980 A CO 12068980A CO 6531489 A2 CO6531489 A2 CO 6531489A2
- Authority
- CO
- Colombia
- Prior art keywords
- genetic engineering
- engineering techniques
- antibody modified
- tslp antibody
- tslp
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención se refiere a compuestos de unión que se unen específicamente a TSLP humana, así como también se refiere a sus usos, por ej., en el tratamiento de trastornos inflamatorios y respuestas inflamatorias alérgicas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25805109P | 2009-11-04 | 2009-11-04 | |
US29700810P | 2010-01-21 | 2010-01-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6531489A2 true CO6531489A2 (es) | 2012-09-28 |
Family
ID=43970291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO12068980A CO6531489A2 (es) | 2009-11-04 | 2012-04-26 | Anticuerpo anti -tslp modificado por técnicas de ingenieria genética |
Country Status (19)
Country | Link |
---|---|
US (2) | US8637019B2 (es) |
EP (2) | EP3594356A1 (es) |
JP (2) | JP6077856B2 (es) |
KR (1) | KR101898739B1 (es) |
CN (1) | CN102782149B (es) |
AR (1) | AR078899A1 (es) |
AU (1) | AU2010315304B2 (es) |
BR (1) | BR112012010707B1 (es) |
CA (1) | CA2779384C (es) |
CL (1) | CL2012001179A1 (es) |
CO (1) | CO6531489A2 (es) |
EC (1) | ECSP12011879A (es) |
ES (1) | ES2784123T3 (es) |
IL (1) | IL219204A0 (es) |
MX (1) | MX2012005180A (es) |
MY (1) | MY162511A (es) |
NZ (1) | NZ599761A (es) |
PE (1) | PE20121646A1 (es) |
WO (1) | WO2011056772A1 (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6077856B2 (ja) * | 2009-11-04 | 2017-02-08 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 操作型抗tslp抗体本出願は、米国特許仮出願第61/297,008号(2010年1月21日出願)、および米国特許仮出願第61/258,051号(2009年11月4日出願)の利益を主張し、該仮出願は各々、引用によりその全体が本明細書に組み込まれる。 |
CA2853247A1 (en) * | 2011-10-28 | 2013-05-02 | Merck Sharp & Dohme Corp. | Il-19 as a biomarker of tslp treatment |
AR090915A1 (es) * | 2012-05-04 | 2014-12-17 | Intervet Int Bv | Proteina de fusion de proteina linfopoyetina estromal timica canina con la region fc de igg |
WO2014031718A1 (en) | 2012-08-23 | 2014-02-27 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to tslp |
US9744210B2 (en) | 2012-12-27 | 2017-08-29 | Massachusetts Eye & Ear Infirmary | Treatment of rhinosinusitis with P-glycoprotein inhibitors |
WO2015187519A1 (en) * | 2014-06-06 | 2015-12-10 | Merck Sharp & Dohme Corp. | Tslp assay |
PT3347377T (pt) * | 2015-09-09 | 2021-04-30 | Novartis Ag | Anticorpos que se ligam à linfopoietina do estroma tímico (tslp) e métodos de utilização dos anticorpos |
MY186352A (en) * | 2015-09-09 | 2021-07-15 | Novartis Ag | Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies |
WO2017066134A1 (en) | 2015-10-16 | 2017-04-20 | Merck Sharp & Dohme Corp. | Processes for preparing formulations for gastrointestinal-targeted therapies |
WO2017123933A1 (en) | 2016-01-15 | 2017-07-20 | Massachusetts Eye And Ear Infirmary | Secreted p-glycoprotein is a non-invasive biomarker of chronic rhinosinusitis |
US20190125826A1 (en) * | 2016-04-22 | 2019-05-02 | Inserm (Institut National De La Santé Et De La Médicale) | Methods and pharmaceutical composition for the treatment of inflammatory skin diseases associated with desmoglein-1 deficiency |
JOP20190055A1 (ar) * | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
MX2019008207A (es) * | 2017-01-09 | 2019-12-11 | Tesaro Inc | Métodos para tratar el cáncer con anticuerpos anti-pd-1. |
JOP20190243A1 (ar) | 2017-04-12 | 2019-10-13 | Medimmune Llc | علاج الربو بجسم مضاد لـ tslp |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
CN110913906A (zh) | 2017-05-02 | 2020-03-24 | 默沙东公司 | 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂 |
CN113853387B (zh) | 2019-06-04 | 2023-04-04 | 江苏恒瑞医药股份有限公司 | 能结合胸腺基质淋巴细胞生成素的抗体及其应用 |
CN112876564B (zh) * | 2019-11-29 | 2022-07-15 | 康诺亚生物医药科技(成都)有限公司 | 一种tslp相关病症治疗剂的开发和应用 |
JP2023505408A (ja) * | 2019-12-13 | 2023-02-09 | シチュアン ケルン-バイオテック バイオファーマシューティカル カンパニー リミテッド | 抗tslp抗体及びその使用 |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
CA3166964A1 (en) | 2020-02-13 | 2021-08-19 | Alexis Lueras | Formulations of human anti-tslp antibodies and methods of treating inflammatory disease |
EP4103605A1 (en) | 2020-02-13 | 2022-12-21 | Amgen Inc. | Treatment of atopic dermatitis with anti-tslp antibody |
JP2023513833A (ja) | 2020-02-18 | 2023-04-03 | アムジェン インコーポレイテッド | ヒト抗tslp抗体の製剤及びそれを使用する方法 |
CN113501878B (zh) * | 2021-02-03 | 2022-12-02 | 北京智仁美博生物科技有限公司 | 针对人tslp的多种抗体及其用途 |
CN113069543B (zh) * | 2021-06-07 | 2021-08-06 | 迈威(上海)生物科技股份有限公司 | 包含抗胸腺基质淋巴细胞生成素的单克隆抗体的液体组合物 |
WO2024163978A2 (en) | 2023-02-02 | 2024-08-08 | Medimmune, Llc | Treatment of chronic rhinosinusitis with anti-tslp antibody |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
EP0438310A1 (en) | 1990-01-19 | 1991-07-24 | Merck & Co. Inc. | Method for producing recombinant immunoglobuline |
EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US6129914A (en) | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
EP1621554B2 (en) | 1992-08-21 | 2012-08-29 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
US5532210A (en) | 1994-06-08 | 1996-07-02 | E. I. Du Pont De Nemours And Company | High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5888530A (en) | 1995-07-21 | 1999-03-30 | The General Hospital Corporation | Method of enhancing delivery of a pharmaceutical formulation |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
DE69833755T2 (de) | 1997-05-21 | 2006-12-28 | Biovation Ltd. | Verfahren zur herstellung von nicht-immunogenen proteinen |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
ES2340112T3 (es) | 1998-04-20 | 2010-05-28 | Glycart Biotechnology Ag | Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos. |
AU6246199A (en) | 1998-09-21 | 2000-04-10 | Schering Corporation | Human interleukin-b50, therapeutic uses |
JP4454859B2 (ja) | 1998-11-13 | 2010-04-21 | イミュネックス・コーポレーション | ヒトtslpdnaおよびポリペプチド |
WO2000039149A2 (en) | 1998-12-30 | 2000-07-06 | Millennium Pharmaceuticals, Inc. | Secreted proteins and uses thereof |
PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Hakko Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
WO2003032898A2 (en) | 2001-07-23 | 2003-04-24 | Immunex Corporation | Modified human thymic stromal lymphopoietin |
MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
EP2311869B2 (en) | 2002-02-01 | 2020-06-17 | Merck Sharp & Dohme Corp. | Use of mammalian cytokine-related reagents |
CN102911987B (zh) | 2002-04-09 | 2015-09-30 | 协和发酵麒麟株式会社 | 基因组被修饰的细胞 |
WO2003086310A2 (en) | 2002-04-12 | 2003-10-23 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
ES2567198T3 (es) * | 2003-01-24 | 2016-04-20 | Applied Molecular Evolution, Inc. | Antagonistas de la IL-1 beta humana |
US7410483B2 (en) | 2003-05-23 | 2008-08-12 | Novare Surgical Systems, Inc. | Hand-actuated device for remote manipulation of a grasping tool |
US8268582B2 (en) | 2003-10-22 | 2012-09-18 | Keck Graduate Institute | Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy |
US20050249712A1 (en) | 2004-03-23 | 2005-11-10 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | Methods for use of TSLP and agonists and antagonists thereof |
EP1593690B1 (en) | 2004-05-05 | 2009-07-01 | Micromet AG | Preparation of ScFv antibody fragments |
US20110142858A1 (en) | 2004-06-07 | 2011-06-16 | Ramot At Tel Aviv University Ltd. | Method of Passsive Immunization Against Disease or Disorder Charcterized by Amyloid Aggregation with Diminished Risk of Neuroinflammation |
JP2008504289A (ja) * | 2004-06-25 | 2008-02-14 | メディミューン,インコーポレーテッド | 部位特異的突然変異誘発による哺乳動物細胞における組換え抗体の産生の増加 |
EP1793856A2 (en) | 2004-08-20 | 2007-06-13 | Amgen Inc. | Methods and compositions for treating allergic inflammation |
US20060171943A1 (en) | 2005-02-01 | 2006-08-03 | Amgen Inc. | Compositions and methods of treating fibrotic disorders |
BRPI0607796A2 (pt) | 2005-02-18 | 2009-06-13 | Medarex Inc | composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica |
CA2513350A1 (en) | 2005-03-02 | 2006-09-02 | Sydney West Area Health Service | Treatment for multiple sclerosis |
JP2006315964A (ja) * | 2005-05-10 | 2006-11-24 | Chugai Pharmaceut Co Ltd | 抗体安定化方法 |
EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
GB0603683D0 (en) | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
EP1891944A1 (en) | 2006-07-24 | 2008-02-27 | Association pour la recherche à l'IGBMC (ARI) | Use of Vitamin D3 agonist in a mammalian model for atopic diseases and of Vitamin D3 antagonists for the treatment of atopic diseases |
JP5120829B2 (ja) | 2006-10-31 | 2013-01-16 | 独立行政法人理化学研究所 | Tslp遺伝子の多型に基づく免疫疾患の検査法 |
SE532251C2 (sv) | 2006-11-28 | 2009-11-24 | Theravac Pharmaceuticals Ab | Nya formuleringar av TSLP för behandling av TH2-medierade inflammatoriska sjukdomar genom vaccinering |
BRPI0720271A2 (pt) * | 2006-12-14 | 2014-01-28 | Schering Corp | Anticorpo anti-tslp projetado |
US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
SI2202245T1 (sl) * | 2007-09-26 | 2016-10-28 | Chugai Seiyaku Kabushiki Kaisha | Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR |
JP6077856B2 (ja) * | 2009-11-04 | 2017-02-08 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 操作型抗tslp抗体本出願は、米国特許仮出願第61/297,008号(2010年1月21日出願)、および米国特許仮出願第61/258,051号(2009年11月4日出願)の利益を主張し、該仮出願は各々、引用によりその全体が本明細書に組み込まれる。 |
-
2010
- 2010-11-02 JP JP2012537186A patent/JP6077856B2/ja active Active
- 2010-11-02 BR BR112012010707-0A patent/BR112012010707B1/pt active IP Right Grant
- 2010-11-02 CN CN201080060560.6A patent/CN102782149B/zh active Active
- 2010-11-02 CA CA2779384A patent/CA2779384C/en active Active
- 2010-11-02 WO PCT/US2010/055062 patent/WO2011056772A1/en active Application Filing
- 2010-11-02 US US13/505,340 patent/US8637019B2/en active Active
- 2010-11-02 EP EP19188884.1A patent/EP3594356A1/en active Pending
- 2010-11-02 MX MX2012005180A patent/MX2012005180A/es active IP Right Grant
- 2010-11-02 AU AU2010315304A patent/AU2010315304B2/en active Active
- 2010-11-02 KR KR1020127011559A patent/KR101898739B1/ko active IP Right Grant
- 2010-11-02 NZ NZ599761A patent/NZ599761A/en not_active IP Right Cessation
- 2010-11-02 MY MYPI2012001964A patent/MY162511A/en unknown
- 2010-11-02 PE PE2012000607A patent/PE20121646A1/es not_active Application Discontinuation
- 2010-11-02 ES ES10828964T patent/ES2784123T3/es active Active
- 2010-11-02 EP EP10828964.6A patent/EP2496707B1/en active Active
- 2010-11-03 AR ARP100104066A patent/AR078899A1/es unknown
-
2012
- 2012-04-15 IL IL219204A patent/IL219204A0/en unknown
- 2012-04-26 CO CO12068980A patent/CO6531489A2/es not_active Application Discontinuation
- 2012-05-04 CL CL2012001179A patent/CL2012001179A1/es unknown
- 2012-05-10 EC ECSP12011879 patent/ECSP12011879A/es unknown
-
2014
- 2014-01-28 US US14/165,986 patent/US20140141012A1/en not_active Abandoned
-
2016
- 2016-03-03 JP JP2016040931A patent/JP2016175894A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2013509862A (ja) | 2013-03-21 |
EP3594356A1 (en) | 2020-01-15 |
RU2012122816A (ru) | 2013-12-10 |
JP6077856B2 (ja) | 2017-02-08 |
EP2496707A4 (en) | 2013-06-26 |
US20140141012A1 (en) | 2014-05-22 |
AU2010315304A1 (en) | 2012-05-17 |
US8637019B2 (en) | 2014-01-28 |
ES2784123T3 (es) | 2020-09-22 |
MX2012005180A (es) | 2012-06-08 |
MY162511A (en) | 2017-06-15 |
KR101898739B1 (ko) | 2018-09-13 |
US20120219565A1 (en) | 2012-08-30 |
BR112012010707B1 (pt) | 2022-08-30 |
CL2012001179A1 (es) | 2012-10-19 |
EP2496707A1 (en) | 2012-09-12 |
WO2011056772A1 (en) | 2011-05-12 |
CN102782149A (zh) | 2012-11-14 |
EP2496707B1 (en) | 2020-02-26 |
KR20120102623A (ko) | 2012-09-18 |
ECSP12011879A (es) | 2012-07-31 |
AU2010315304B2 (en) | 2014-03-27 |
IL219204A0 (en) | 2012-06-28 |
BR112012010707A2 (pt) | 2020-08-25 |
NZ599761A (en) | 2014-04-30 |
CA2779384C (en) | 2018-02-27 |
PE20121646A1 (es) | 2012-12-02 |
CA2779384A1 (en) | 2011-05-12 |
CN102782149B (zh) | 2014-11-12 |
AR078899A1 (es) | 2011-12-14 |
JP2016175894A (ja) | 2016-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP12011879A (es) | Anticuerpo anti-tslp modificado por técnicas de ingeniería genética | |
CY1121862T1 (el) | Αντισωματα anti-phf-tau και χρησεις αυτων | |
DOP2011000333A (es) | Inmunoglobulina con dominio variable dual y usos de la mismas | |
AR083044A1 (es) | Anticuerpos anti-cd48 y usos de los mismos | |
CO6511254A2 (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
UY31861A (es) | Inmunoglobulina con dominio variable dual y usos de la misma | |
DOP2010000368A (es) | Inmunoglobulinas con dominio variable dual y usos de la misma | |
CO6771416A2 (es) | Inmunoglobulinas de dominio variable dual biespecíficas de il-1 alfa y beta y su uso | |
UY32060A (es) | Anticuerpos anti-il-13 obtenidos mediante ingeniería, composiciones , métodos y usos | |
CO6420355A2 (es) | Anticuerpos biespecíficos anti-erbb-3/anti-c-met | |
CO6680687A2 (es) | Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas | |
ECSP10010475A (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
UY32808A (es) | Inmunoglobulinas como dominio variable dual y usos de las mismas | |
CO6551674A2 (es) | Anticuerpos anti-her3 y usos de los mismo | |
UY33202A (es) | Proteínas de unión a cd127 | |
BR112014026740A8 (pt) | anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo | |
UA107822C2 (en) | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor. | |
EA201270228A1 (ru) | Полноценные человеческие антитела к btla | |
ECSP12012105A (es) | Antídotos de Anticoagulantes | |
CO6351748A2 (es) | Anticuerpos contra il-6 y sus usos | |
AR091305A1 (es) | ANTICUERPOS ANTI-IgE Y SUS METODOS DE USO | |
EA201590402A1 (ru) | ЧЕЛОВЕЧЕСКИЕ АНТИТЕЛА ПРОТИВ GFRα3 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
BR112013005855A2 (pt) | heteroarilas fundidas e seus usos | |
ECSP13012536A (es) | Composiciones de anticuerpo y métodos de uso | |
BR112013012858A2 (pt) | anticorpos que se ligam a pectina acetilesterase de notum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |